On September 24, Moderna, Inc. fell 3.01% in pre-market trading, trading at $176.5/share, with turnover of $5.58 million. The decline follows a session in which the stock surged over 5% and touched $192.31, its highest level since January 2023.

The pullback comes after an extraordinary rally driven by the company's personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck, which achieved positive Phase 3 INTerpath-001 trial results in melanoma — the first mRNA cancer therapy validated in a randomized Phase 3 study. The stock has gained over 100% in the past month and more than 500% year-to-date. Market participants have noted that a considerable portion of positive expectations has already been priced in ahead of the full melanoma data presentation scheduled for October 24 at the ESMO annual meeting. Notably, UBS maintains a neutral rating with a $150 price target, well below recent trading levels, while Rothschild & Co Redburn holds a sell rating with an $81 target, underscoring a widening gap between bullish momentum and analyst consensus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)